340B Reporting and Accountability Act

Bill 118 s 1182, also known as the 340B Reporting and Accountability Act, is a piece of legislation introduced in the US Congress. The bill aims to increase transparency and accountability in the 340B Drug Pricing Program, which requires drug manufacturers to provide discounts on outpatient drugs to certain healthcare facilities serving low-income and vulnerable populations.

The key provisions of the bill include requiring participating healthcare facilities to report on the use of 340B discounts, including the amount of discounts received and how they are used. The bill also calls for the establishment of a publicly accessible database to track and monitor the use of 340B discounts by healthcare facilities.

Additionally, the bill seeks to improve oversight of the 340B program by requiring the Health Resources and Services Administration (HRSA) to conduct regular audits of participating healthcare facilities to ensure compliance with program requirements. The bill also includes provisions to address concerns about the potential for abuse and misuse of 340B discounts. Overall, the 340B Reporting and Accountability Act aims to enhance transparency and accountability in the 340B Drug Pricing Program to ensure that the program is effectively serving its intended purpose of providing affordable medications to underserved populations.